Medibank Private

The Business

Health insurance is the core of the company, contributing around 93% of group revenue through two brands: Medibank for the premium segment and ahm for value-conscious buyers, together addressing more than 80% of the addressable market. The company holds roughly 27% market share, co-leading the industry alongside Bupa. A smaller but faster-growing division, Medibank Health, runs primary care clinics, home hospital services and mental health support, contributing around 7% of group revenue but a rising share of strategic value.

Recent Performance

Revenue grew 5.9% in FY26 to $9,115m, up from $8,604m in FY25. Net profit jumped 27.5% to $639m, but a meaningful chunk of that was a one-off: a $74.8m COVID-era claims reversal as actual healthcare utilisation came in below what had been provisioned. Strip that out and underlying earnings growth was considerably more modest. The shares have traded in a narrow band for some time, consistent with the market treating this as a stable income holding rather than a re-rating story.

Outlook

Revenue growth is expected to ease gradually over the next few years, as regulated premium increases in the mid-single digits offset softening policyholder volumes. The COVID claims tailwind that flattered FY26 reverses over the coming year, pushing the loss ratio back up and compressing gross margin before it recovers modestly. A cybercrime settlement, if it lands where we assume, would weigh on earnings growth in one of the next two years before growth rebounds. Medibank Health is the swing factor for the medium-term outlook, with management targeting a substantial step-up in annual profit from the division by the end of the decade.

Key Risks

The largest single risk is the outstanding cybercrime litigation. A penalty at the severe end of what is legally possible would be large enough to force a dilutive capital raise, given the scale of compromised records and the potential for civil penalties to be assessed per affected individual. A second, more gradual risk is the ongoing shift by cost-conscious policyholders toward cheaper cover, a mix change that is already visible in widening margin drag and would continue to weigh on gross margin if sustained. Third, the regulated pricing framework itself caps operating margin in a narrow band, which limits how much structural earnings growth or margin expansion the business can generate even if it executes well.

What to Watch

• September 2026 Cybercrime mediation outcome — the thesis-defining event. A modest settlement removes the overhang, while a larger figure confirms the tail risk embedded in our modelling.
• February 2027 1H27 results — first clean half since the COVID reversal, validating whether Medibank Health's profit trajectory is on track.
• Next 12-24 months RBA rate path — rate cuts would trim investment income but could support a higher earnings multiple.

Company Description

Health Insurance is the dominant division, covering resident and non-resident policyholders under two distinct brands. Medibank targets the premium end of the market while ahm competes on price, together reaching more than 80% of the addressable customer base. This dual-brand structure lets the company defend market share across income segments without diluting either brand's positioning. Medibank Health, the smaller division at around 7% of group revenue, runs primary care clinics (including the Myhealth and Better Medical networks), home hospital care, mental health services and telehealth, generating $101m of profit in FY26.

Where the Growth Is

Medibank Health is the company's clearest growth lever. From $101m of profit in FY26, it has been growing 25-31% a year, a pace expected to decelerate toward 5% by the mid-2030s as the base scales. Management's aspiration is $200m-plus in annual profit by FY30, implying $100-150m of incremental profit growth over the next several years, roughly double the division's current earnings contribution.

Competitive Position

The core insurance business benefits from durable, largely regulatory advantages. APRA capital requirements and ministerial approval of premium increases create meaningful barriers to new entrants, and no major new competitor has entered the market in decades. Scale reinforces this: with roughly 27% market share held steady over recent periods, the company's expense ratio benefits from spreading fixed costs over a larger policyholder base than most rivals can match. The dual-brand strategy lets it compete for both premium and value-conscious customers without cannibalising either segment. These advantages appear durable for the next five to seven years, though they cap upside as much as they protect the downside: the same regulatory framework that shields margins also prevents them expanding materially higher.

Management & Capital Discipline

Capital allocation has been disciplined: an 82.5% fully franked payout ratio, funded entirely from operating cash flow, alongside opportunistic bolt-on acquisitions in the health services space, all without resorting to leverage. On delivery, management has hit its own margin guidance for three consecutive years, a genuine track record in an industry where claims volatility can easily wrong-foot forecasts. The gap worth flagging: management has provided specific guidance on legal costs from the cybercrime litigation (under $20m) but has offered no quantified view on the potential penalty itself, an omission that risks anchoring investors to an overly benign outcome.

Financial Position

The balance sheet is close to debt-free, with only $36m of corporate debt against an insurance capital buffer running at roughly 1.9 times the regulatory minimum, comfortably above the 1.7 times target. Liquidity is ample and the investment portfolio backing policyholder claims is separate from operating cash needs. This is a company that could absorb a significant one-off shock, including a large litigation settlement, without threatening its dividend or requiring emergency capital, short of the most extreme outcomes modelled in our severe scenario.